These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10367593)

  • 1. Interspecies comparison of the antiplatelet, antithrombotic, and hemorrhagic effects of SR 121566A, a novel nonpeptide GP IIb/IIIa antagonist.
    Bernat A; Hoffmann P; Savi P; Lalé A; Herbert JM
    J Cardiovasc Pharmacol; 1999 Jun; 33(6):897-904. PubMed ID: 10367593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet and antithrombotic efficacy of SR 121787, a nonpeptide orally active GP IIb/IIIa antagonist, in rabbits: comparison with clopidogrel and aspirin.
    Hoffmann P; Bernat A; Savi P; Herbert JM
    J Cardiovasc Pharmacol; 1997 Sep; 30(3):360-6. PubMed ID: 9300321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of a novel glycoprotein IIb/IIIa antagonist, SR 121566A, on platelet aggregation and activation in rhesus monkeys.
    Orcullo Santillan MK; Herring J; Hoppensteadt DA; Jeske W; Herbert JM; Fareed J
    Clin Appl Thromb Hemost; 2001 Jan; 7(1):10-5. PubMed ID: 11190897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist.
    Hoffmann P; Bernat A; Savi P; Herbert JM
    J Pharmacol Exp Ther; 1998 Aug; 286(2):670-5. PubMed ID: 9694919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist.
    Moritani Y; Sato K; Shigenaga T; Hisamichi N; Ichihara M; Akamatsu S; Suzuki Ki; Nii T; Kaku S; Kawasaki T; Matsumoto Y; Inagaki O; Tomioka K; Yanagisawa I
    Eur J Pharmacol; 2002 Mar; 439(1-3):43-52. PubMed ID: 11937091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
    Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM
    J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
    J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
    Kawamura M; Imura Y; Moriya N; Kita S; Fukushi H; Sugihara H; Nishikawa K; Terashita Z
    J Pharmacol Exp Ther; 1996 Apr; 277(1):502-10. PubMed ID: 8613960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SR 121787, a new orally active fibrinogen receptor antagonist.
    Savi P; Badorc A; Lalé A; Bordes MF; Bornia J; Labouret C; Bernat A; de Cointet P; Hoffmann P; Maffrand JP; Herbert JM
    Thromb Haemost; 1998 Sep; 80(3):469-76. PubMed ID: 9759629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antithrombotic efficacy of the GP IIb/IIIa antagonist SR121787 is potentiated by antithrombin-dependent factor Xa inhibition without an increase in the bleeding risk in the rabbit.
    Bernat A; Savi P; Lale A; Hoffmann P; Herbert JM
    J Cardiovasc Pharmacol; 1999 Apr; 33(4):573-9. PubMed ID: 10218727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel nonpeptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specificity.
    Mousa SA; Forsythe M; Lorelli W; Bozarth J; Xue CB; Wityak J; Sielecki TM; Olson RE; DeGrado W; Kapil R; Hussain M; Wexler R; Thoolen MJ; Reilly TM
    Coron Artery Dis; 1996 Oct; 7(10):767-74. PubMed ID: 8970768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-platelet and anti-thrombosis characteristics of Z4A5, a novel selective platelet glycoprotein IIb/IIIa inhibitor, compared with eptifibatide under long-term infusion.
    Shi XL; Shen S; Guo MM; Zhang GJ; Che J; Wang B; Zhou J
    Pharmazie; 2015 Dec; 70(12):810-4. PubMed ID: 26817279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist.
    Mousa SA; DeGrado WF; Mu DX; Kapil RP; Lucchesi BR; Reilly TM
    Circulation; 1996 Feb; 93(3):537-43. PubMed ID: 8565173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
    Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
    Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of aspirin on platelet desaggregation induced by SR121566, a potent GP-IIb/IIIa antagonist.
    Savi P; Bernat A; Lalé A; Roque C; Zamboni G; Herbert JM
    Platelets; 2000 Feb; 11(1):43-8. PubMed ID: 10938881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active.
    Cook NS; Bruttger O; Pally C; Hagenbach A
    Thromb Haemost; 1993 Nov; 70(5):838-47. PubMed ID: 8128443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs.
    Ogawa T; Sugidachi A; Naganuma H; Asai F
    Thromb Res; 2000 Mar; 97(5):307-15. PubMed ID: 10709906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217.
    Cook JJ; Holahan MA; Lyle EA; Ramjit DR; Sitko GR; Stranieri MT; Stupienski RF; Wallace AA; Hand EL; Gehret JR; Kothstein T; Drag MD; McCormick GY; Perkins JJ; Ihle NC; Duggan ME; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1996 Jul; 278(1):62-73. PubMed ID: 8764336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic activity of Z4A5, a new platelet glycoprotein IIb/IIIa receptor antagonist evaluated in a rabbit arteriovenous shunt thrombosis model.
    Jing BB; Li YX; Zhang H; Ren ST; Wang M; Li YP; Zang WJ; Wang B
    Thromb Res; 2011 Nov; 128(5):463-9. PubMed ID: 21924458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.